Amgen's Kyprolis bests Velcade in new Phase III myeloma trial
This article was originally published in Scrip
Amgen/ Onyx's second-generation proteasome inhibitor Kyprolis (carfilzomib) has doubled progression-free survival in patients with relapsed multiple myeloma in the head-to-head ENDEAVOR trial that pitted it against Takeda's older proteasome inhibitor bortezomib (Velcade).
You may also be interested in...
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.